{"mainPropery":{"diseaseId":12798,"diseaseName":"Early-onset, autosomal dominant Alzheimer disease","hasGardWebPage":true,"isRare":true,"websiteUrl":"https://rarediseases.info.nih.gov/diseases/12798/early-onset-autosomal-dominant-alzheimer-disease","synonyms":["EOFAD","Early-onset familial autosomal dominant Alzheimer disease","Early-onset autosomal dominant Alzheimer disease","Familial Alzheimer disease"],"synonyms-with-source":[{"name":"EOFAD","source":"Orphanet"},{"name":"Early-onset familial autosomal dominant Alzheimer disease","source":"Orphanet"},{"name":"Early-onset autosomal dominant Alzheimer disease","source":"OrphaData.Org"},{"name":"Familial Alzheimer disease","source":"OrphaData.Org"}],"identifiers":[{"identifierType":"ORPHANET","identifierId":"1020"}]},"diseaseCategories":[{"diseaseTypeId":5,"diseaseTypeName":"Congenital and Genetic Diseases","source":"Orphanet"},{"diseaseTypeId":17,"diseaseTypeName":"Nervous System Diseases","source":"Orphanet"}],"organizations":[{"resourceID":68,"resourceName":"Alzheimer's Association","abbreviation":"","address1":"225 N. Michigan Ave., Fl. 17","address2":"","address3":"","address4":"","address5":"","city":"Chicago","state":"IL","zip":"60601-7633 ","country":"United States","phone":"","tty":"1-866-403-3073 ","tollFree":"1-800-272-3900  (24/7 Helpline)","fax":"1-866-699-1246 ","email":"info@alz.org","url":"https://www.alz.org/","freeText":""},{"resourceID":528,"resourceName":"Alzheimer's Disease Education and Referral Center (ADEAR)","abbreviation":"","address1":"P.O. Box 8250","address2":"","address3":"","address4":"","address5":"","city":"Silver Spring","state":"MD","zip":"20907-8250","country":"United States","phone":"+1-301-495-3311 ","tty":"","tollFree":"1-800-438-4380","fax":"+1-301-495-3334","email":" adear@nia.nih.gov","url":"https://www.nia.nih.gov/health/alzheimers","freeText":""},{"resourceID":530,"resourceName":"Alzheimer's Foundation of America","abbreviation":"","address1":"322 Eighth Avenue","address2":"7th Floor","address3":"","address4":"","address5":"","city":"New York","state":"NY","zip":"10001","country":"United States","phone":"","tty":"","tollFree":"1-866-232-8484 (National Helpline)","fax":"+1-646-638-1546","email":"info@alzfdn.org","url":"https://alzfdn.org/","freeText":""}],"resource descriptions":[{"id":8,"resourceId":11,"resourceName":"PubMed","descriptionText":"<a href='http://www.ncbi.nlm.nih.gov/pubmed?term=Alzheimer%20disease%5Btitle%5D%20AND%20familial%5Btitle%5D%20AND%20%28autosomal%5BAll%20Fields%5D%20AND%20dominant%5BAll%20Fields%5D%29&cmd=DetailsSearch' target='_blank'>PubMed</a> is a searchable database of medical literature and lists journal articles that discuss Early-onset, autosomal dominant Alzheimer disease. Click on the link to view a sample search on this topic.","resourceClassificationName":"Overview","resourceClassificationSectionName":"In-Depth Information"},{"id":9,"resourceId":12,"resourceName":"ClinicalTrials.gov","descriptionText":"<a href='https://clinicaltrials.gov/ct2/results?term=early+onset+Alzheimer+disease&type=&rslt=&recr=Open&age_v=&gndr=&cond=&intr=&titles=&outc=&spons=&lead=&id=&state1=&cntry1=&state2=&cntry2=&state3=&cntry3=&locn=&rcv_s=&rcv_e=&lup_s=&lup_e=' target='_blank'>ClinicalTrials.gov</a> lists trials that are related to Early-onset, autosomal dominant Alzheimer disease. Click on the link to go to ClinicalTrials.gov to read descriptions of these studies. <br />\r\n<br />\r\n<em><strong>Please note:</strong>&nbsp;Studies listed on the&nbsp;ClinicalTrials.gov&nbsp;website are listed for informational purposes only; being listed does not reflect an endorsement by GARD or the NIH. We strongly recommend that you talk with a trusted healthcare provider before choosing to participate in any clinical study.</em>","resourceClassificationName":"Research","resourceClassificationSectionName":"Clinical Research Resources"},{"id":10,"resourceId":13,"resourceName":"MedlinePlus Genetics","descriptionText":"<a href='http://ghr.nlm.nih.gov/condition/alzheimer-disease' target='_blank'>Genetics Home Reference (GHR)</a> contains information on Early-onset, autosomal dominant Alzheimer disease. This website is maintained by the National Library of Medicine.<br />\r\n","resourceClassificationName":"Overview","resourceClassificationSectionName":"Where to Start"},{"id":1526,"resourceId":2158,"resourceName":"Genetic Testing Registry","descriptionText":"The <a href='https://www.ncbi.nlm.nih.gov/gtr/conditions/CN043596/' target='_blank'>Genetic Testing Registry</a> (GTR) provides information about the genetic tests for this condition. The intended audience for the GTR is health care providers and researchers. Patients and consumers with specific questions about a genetic test should contact a health care provider or a genetics professional.<br />\r\n","resourceClassificationName":"Diagnosis","resourceClassificationSectionName":"Testing Resources"},{"id":1534,"resourceId":2165,"resourceName":"Orphanet","descriptionText":"<a href='http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1020' target='_blank'>Orphanet</a> is a European reference portal for&nbsp;information on rare diseases and orphan drugs. Access to this database is free of charge.<br />\r\n","resourceClassificationName":"Overview","resourceClassificationSectionName":"In-Depth Information"},{"id":1537,"resourceId":2168,"resourceName":"GeneReviews","descriptionText":"<a href='http://www.ncbi.nlm.nih.gov/books/NBK1236/' target='_blank'>GeneReviews</a> provides current, expert-authored, peer-reviewed, full-text articles describing the application of genetic testing to the diagnosis, management, and genetic counseling of patients with specific inherited conditions.<br />\r\n","resourceClassificationName":"Overview","resourceClassificationSectionName":"In-Depth Information"},{"id":1572,"resourceId":2190,"resourceName":"National Institute on Aging","descriptionText":"The <a href='https://www.nia.nih.gov/alzheimers/publication/alzheimers-disease-genetics-fact-sheet' target='_blank'>National Institute on Aging</a> (NIA) leads a national program of research on the biomedical, social, and behavioral aspects of the aging process; the prevention of age-related diseases and disabilities; and the promotion of a better quality of life for all older Americans. Click on the link to view information on this topic. ","resourceClassificationName":"Overview","resourceClassificationSectionName":"Where to Start"},{"id":2135,"resourceId":3342,"resourceName":"Monarch Initiative","descriptionText":"The <a href='https://monarchinitiative.org/disease/Orphanet:1020' target='_blank'>Monarch Initiative</a> brings together data about this condition from humans and other species to help physicians and biomedical researchers. Monarch&rsquo;s tools are designed to make it easier to compare the signs and symptoms (phenotypes) of different diseases and discover common features. This initiative is a collaboration between several academic institutions across the world and is funded by the National Institutes of Health. Visit the website to explore the biology of this condition.","resourceClassificationName":"Overview","resourceClassificationSectionName":"In-Depth Information"},{"id":2319,"resourceId":68,"resourceName":"Alzheimer's Association","descriptionText":"The&nbsp;<a href='http://www.alz.org/research/science/alzheimers_disease_causes.asp#genetics' target='_blank'>Alzheimer's Association</a> provides information on the genetics of Alzheimer disease, including information on&nbsp;Early-onset, autosomal dominant Alzheimer disease","resourceClassificationName":"Overview","resourceClassificationSectionName":"Where to Start"},{"id":2320,"resourceId":3557,"resourceName":"Dominantly Inherited Alzheimer Network (DIAN)","descriptionText":"The <a href='https://dian.wustl.edu/' target='_blank'>Dominantly Inherited Alzheimer Network (DIAN)</a>&nbsp;is an international partnership of leading scientists determined to understand dominantly inherited Alzheimer disease (DIAD).&nbsp;The Dominantly Inherited Alzheimer Network Trials Unit (DIAN-TU), the clinical research arm of DIAN,&nbsp;is dedicated to designing and managing interventional therapeutic trials for individuals with, and at risk of, DIAD. Click on the link to learn about their research efforts and see enrollment information for individuals and families who are impacted by DIAD or who are at risk for developing the disease.","resourceClassificationName":"Research","resourceClassificationSectionName":"General Clinical Trials & Research"},{"id":2340,"resourceId":3583,"resourceName":"Job Accommodation Network","descriptionText":"The <a href='https://askjan.org/disabilities/Alzheimer-s-Disease.cfm' target='_blank'>Job Accommodation Network</a> (JAN) has information on workplace accommodations and disability employment issues related to this condition. JAN is a service of the Office of Disability Employment Policy in the U.S. Department of Labor.","resourceClassificationName":"Living With","resourceClassificationSectionName":"Community Resources"},{"id":2722,"resourceId":4053,"resourceName":"Patient Registry","descriptionText":"A registry supports research by collecting of information about patients that share something in common, such as being diagnosed with Early-onset, autosomal dominant Alzheimer disease. The type of data collected can vary from registry to registry and is based on the goals and purpose of that registry. Some registries collect contact information while others collect more detailed medical information. <a href=\"https://www.nih.gov/health-information/nih-clinical-research-trials-you/list-registries\" target=\"_blank\">Learn more about registries</a>.<br />\r\n<br />\r\nRegistries for&nbsp;Early-onset, autosomal dominant Alzheimer disease:<br />\r\n<a href='https://www.endalznow.org/about-the-registry/how-the-registry-works' target='_blank'>Alzheimer's Prevention Registry</a><br /><a href='https://dian.wustl.edu/our-research/registry/' target='_blank'>Dominantly Inherited Alzheimer Network (DIAN) Expanded Registry</a><br />&nbsp;","resourceClassificationName":"Research","resourceClassificationSectionName":"Patient Registry"}],"overviewQuestion":{"questionId":9633,"questionText":"What is early-onset, autosomal dominant Alzheimer disease?","answerText":"<strong>Early-onset, autosomal dominant Alzheimer disease</strong> is a form of <a href=\"https://rarediseases.info.nih.gov/gard/10254/alzheimer-disease/Resources/1\" target=\"_blank\">Alzheimer disease</a> (AD) that develops before the age of 65. It is diagnosed in families that have more than one member with AD (usually multiple&nbsp;persons in more than one generation) in which the age of onset is consistently before age 60  and often between <span>the ages of 30 and 60 years.</span> In general, AD is a degenerative disease of the brain that causes gradual loss of memory, judgement, and the ability to function socially.[9920][13399]&nbsp;<br />\r\n<br />\r\nThere are three subtypes of early-onset familial AD which are each associated with changes (<a class=\"anchor_glossary\" target=\"_blank\">mutations</a>) in unique&nbsp;<glossary class=\"glossarizer_replaced\" group=\"readSpeaker_Summary\" parent=\"167\" glossaryid=\"809\" term=\"Gene\">genes</glossary>:[9920][13399]<br />\r\n<br />\r\n(1) Alzheimer disease, type 1&nbsp;is caused by mutations in the&nbsp;<em><a class=\"external-link1 confirmation\" href=\"http://ghr.nlm.nih.gov/gene/APP\" target=\"_blank\">APP</a></em>&nbsp;gene<br />\r\n(2) Alzheimer disease, type&nbsp;3&nbsp;is caused by mutations in the&nbsp;<em><a class=\"external-link1 confirmation\" href=\"http://ghr.nlm.nih.gov/gene/PSEN1\" target=\"_blank\">PSEN1</a></em>&nbsp;gene &nbsp;&nbsp;&nbsp;&nbsp;<br />\r\n(3) Alzheimer disease, type 4&nbsp;is caused by mutations in the&nbsp;<em><a class=\"external-link1 confirmation\" href=\"http://ghr.nlm.nih.gov/gene/PSEN2\" target=\"_blank\">PSEN2</a></em>&nbsp;gene.&nbsp;<br />\r\n<br />\r\nAll subtypes are inherited in an <a href=\"http://www.nlm.nih.gov/medlineplus/ency/article/002049.htm\" target=\"_blank\">autosomal dominant</a> manner. There is no cure for AD. Treatment is supportive and based on the signs and symptoms present in each person.[9920]<br />\r\n&nbsp;","dateModified":"2017-05-05T00:00:00"},"basicQuestions":[{"questionId":9631,"questionText":"How is early-onset, autosomal dominant Alzheimer disease inherited?","answerText":"Early-onset, autosomal dominant Alzheimer disease is inherited in an <a href=\"http://www.nlm.nih.gov/medlineplus/ency/article/002049.htm\" target=\"_blank\">autosomal dominant</a> manner.[9920] This means that to be affected, a person only needs a change (<a href=\"http://www.genome.gov/glossary/index.cfm?id=134\" target=\"_blank\">mutation</a>) in one copy of the responsible <a href=\"http://www.genome.gov/glossary/index.cfm?id=70\" target=\"_blank\">gene</a> in each cell. In some cases, an affected person inherits the mutation from an affected parent. Other cases may result from new (<a href=\"http://www.ghr.nlm.nih.gov/glossary=denovomutation\" target=\"_blank\">de novo</a>) mutations in the gene. These cases occur in people with no history of the disorder in their family. A person with this condition has a 50% chance with each pregnancy of passing along the altered gene to his or her child.","dateModified":"2015-11-02T20:19:00","resourceClassificationName":"Inheritance","references":[{"referenceId":9920,"authors":"Bird TD","articleTitle":"Early-Onset Familial Alzheimer Disease","bookWebsiteJournalTitle":"GeneReviews","date":"October 2012","volume":"","pages":"","url":"http://www.ncbi.nlm.nih.gov/books/NBK1236/","authors2":"","placeOfPublication":"","publisher":""}]},{"questionId":11689,"questionText":"How is early-onset, autosomal dominant Alzheimer disease diagnosed?","answerText":"Early-onset, autosomal dominant Alzheimer disease is diagnosed in families that have more than one member with AD  in which the age of onset is before age 60 to 65 years. Genetic testing and identification of a mutation in one of the implicated genes (<em><a href=\"https://ghr.nlm.nih.gov/gene/PSEN1\" target=\"_blank\">PSEN1</a></em>, <em><a href=\"https://ghr.nlm.nih.gov/gene/APP\" target=\"_blank\">APP</a></em>, or<em> <a href=\"https://ghr.nlm.nih.gov/gene/PSEN2\" target=\"_blank\">PSEN2</a></em>) in an affected family member can assist in confirming the diagnosis. Not all families with early-onset, autosomal dominant Alzheimer disease are found to have mutations in one of the three known genes; therefore there may be other genes involved that have not yet been reported.[9920]","dateModified":"2017-03-10T11:50:00","resourceClassificationName":"Diagnosis","references":[{"referenceId":9920,"authors":"Bird TD","articleTitle":"Early-Onset Familial Alzheimer Disease","bookWebsiteJournalTitle":"GeneReviews","date":"October 2012","volume":"","pages":"","url":"http://www.ncbi.nlm.nih.gov/books/NBK1236/","authors2":"","placeOfPublication":"","publisher":""}]},{"questionId":11690,"questionText":"How might early-onset, autosomal dominant Alzheimer disease be treated?","answerText":"Unfortunately, there is no cure for Alzheimer disease in general; however, there are medications that may assist in temporarily helping with memory and thinking problems, such as <a href=\"https://medlineplus.gov/druginfo/meds/a602009.html\" target=\"_blank\">Exelon</a>, <a href=\"https://medlineplus.gov/druginfo/meds/a699058.html\" target=\"_blank\">Galantamine</a>, and <a href=\"https://medlineplus.gov/druginfo/meds/a697032.html\" target=\"_blank\">Aricept</a>. Physical and occupational therapy can be helpful in managing problems with walking and activities of daily living. Depression and seizures may be treated with appropriate medications.[9920]","dateModified":"2017-03-10T14:05:00","resourceClassificationName":"Treatment","references":[{"referenceId":9920,"authors":"Bird TD","articleTitle":"Early-Onset Familial Alzheimer Disease","bookWebsiteJournalTitle":"GeneReviews","date":"October 2012","volume":"","pages":"","url":"http://www.ncbi.nlm.nih.gov/books/NBK1236/","authors2":"","placeOfPublication":"","publisher":""}]}],"references":[],"relatedDiseases":[{"relatedDiseaseId":10254,"relatedDiseaseName":"Alzheimer disease","relation":"Parent","isRare":false,"hasGardPage":true},{"relatedDiseaseId":9465,"relatedDiseaseName":"Alzheimer disease type 1","relation":"Child","isRare":true,"hasGardPage":false},{"relatedDiseaseId":9468,"relatedDiseaseName":"Alzheimer disease type 3","relation":"Child","isRare":true,"hasGardPage":false},{"relatedDiseaseId":9469,"relatedDiseaseName":"Alzheimer disease type 4","relation":"Child","isRare":true,"hasGardPage":false},{"relatedDiseaseId":632,"relatedDiseaseName":"Familial Alzheimer disease","relation":"Parent","isRare":true,"hasGardPage":true}],"gardCases":[],"news":[{"newsId":667,"dateCreated":"2019-10-02T11:16:00","publishDate":"2019-10-02T00:00:00","title":"New NIH-funded Research Centers Speed and Diversify Alzheimer’s Drug Discovery","description":"To help meet the urgent need for therapies that will effectively treat or prevent Alzheimer&rsquo;s disease, the National Institute on Aging (NIA) has launched two new research centers with funding expected to total more than $73 million over the next five years. The Alzheimer Centers for the Discovery of New Medicines are designed to diversify and reinvigorate the Alzheimer&rsquo;s disease drug development pipeline. NIA is part of the National Institutes of Health.","url":"https://www.nih.gov/news-events/news-releases/new-nih-funded-translational-research-centers-speed-diversify-alzheimers-drug-discovery","lastModified":"2020-05-22T11:53:00","isFeatured":false},{"newsId":665,"dateCreated":"2019-08-27T11:17:00","publishDate":"2019-08-27T00:00:00","title":"Tissue Model Reveals Role of Blood-Brain Barrier in Alzheimer’s","description":"The blood-brain barrier is the normally tight border that prevents harmful molecules in the bloodstream from entering the brain.  A recent study found that the blood-brain barrier can be damaged by the protein aggregates that form in the brains of Alzheimer&rsquo;s patients. This allows toxins to enter the brain, further harming neurons. Researchers at MIT have found a drug, etodolac, that restores the blood-brain barrier and continue to search for effective drugs.","url":"http://news.mit.edu/2019/alzheimers-model-blood-brain-0812","lastModified":"2019-08-27T11:17:00","isFeatured":false},{"newsId":671,"dateCreated":"2020-05-20T13:39:00","publishDate":"2020-05-22T00:00:00","title":"NIH-Supported Research Survey to Examine Impact of COVID-19 on Rare Diseases Community","description":"The NIH-funded Rare Diseases Clinical Research Network (RDCRN) has launched an <a href=\"https://www.rarediseasesnetwork.org/COVIDsurvey \" target=\"_blank\">online research survey</a> to find out how the COVID-19 pandemic is impacting individuals with rare diseases, their families and their caregivers. Your participation can help the rare disease research community shed light on the needs of people with rare diseases during this and other potential health crises, in addition to informing future research efforts. The survey must be completed by December 15, 2020.","url":"https://www.rarediseasesnetwork.org/COVIDsurvey","lastModified":"2020-11-30T14:44:00","isFeatured":false}],"conferences":[],"phenoTypes":[{"phenoTypeId":2455,"phenoTypeName":"Abnormal social behavior","frequencyText":"Very frequent","percentRanges":"80%-99%"},{"phenoTypeId":6010,"phenoTypeName":"Agitation","frequencyText":"Very frequent","percentRanges":"80%-99%"},{"phenoTypeId":13743,"phenoTypeName":"Cerebral cortical atrophy","frequencyText":"Very frequent","percentRanges":"80%-99%"},{"phenoTypeId":9380,"phenoTypeName":"Confusion","frequencyText":"Very frequent","percentRanges":"80%-99%"},{"phenoTypeId":5312,"phenoTypeName":"Deposits immunoreactive to beta-amyloid protein","frequencyText":"Very frequent","percentRanges":"80%-99%"},{"phenoTypeId":14131,"phenoTypeName":"Hallucinations","frequencyText":"Very frequent","percentRanges":"80%-99%"},{"phenoTypeId":8734,"phenoTypeName":"Hypertonia","frequencyText":"Very frequent","percentRanges":"80%-99%"},{"phenoTypeId":5218,"phenoTypeName":"Language impairment","frequencyText":"Very frequent","percentRanges":"80%-99%"},{"phenoTypeId":11437,"phenoTypeName":"Memory impairment","frequencyText":"Very frequent","percentRanges":"80%-99%"},{"phenoTypeId":10639,"phenoTypeName":"Myoclonus","frequencyText":"Very frequent","percentRanges":"80%-99%"},{"phenoTypeId":13857,"phenoTypeName":"Neurofibrillary tangles","frequencyText":"Very frequent","percentRanges":"80%-99%"},{"phenoTypeId":9388,"phenoTypeName":"Parkinsonism","frequencyText":"Very frequent","percentRanges":"80%-99%"},{"phenoTypeId":8719,"phenoTypeName":"Seizure","frequencyText":"Very frequent","percentRanges":"80%-99%"},{"phenoTypeId":14128,"phenoTypeName":"Disinhibition","frequencyText":"Frequent","percentRanges":"30%-79%"},{"phenoTypeId":5613,"phenoTypeName":"Abnormality of vision","frequencyText":"Occasional","percentRanges":"5%-29%"},{"phenoTypeId":5157,"phenoTypeName":"Aphasia","frequencyText":"Occasional","percentRanges":"5%-29%"},{"phenoTypeId":8720,"phenoTypeName":"Ataxia","frequencyText":"Occasional","percentRanges":"5%-29%"},{"phenoTypeId":11076,"phenoTypeName":"Dysgraphia","frequencyText":"Occasional","percentRanges":"5%-29%"},{"phenoTypeId":11075,"phenoTypeName":"Finger agnosia","frequencyText":"Occasional","percentRanges":"5%-29%"},{"phenoTypeId":8715,"phenoTypeName":"Intellectual disability","frequencyText":"Occasional","percentRanges":"5%-29%"},{"phenoTypeId":10133,"phenoTypeName":"Oculomotor apraxia","frequencyText":"Occasional","percentRanges":"5%-29%"},{"phenoTypeId":15361,"phenoTypeName":"Semantic dementia","frequencyText":"Occasional","percentRanges":"5%-29%"}],"medicalProducts":[],"EncodedName":"Early-onset,_autosomal_dominant_Alzheimer_disease"}